Diavitol solution for injections in ampoules 5ml №5×2

Name:
Diavitol solution for injection in amp.5 ml in pack No. 5×2
Description:
Colorless to yellowish transparent solution with a specific odor, practically free from particles Product formSolution Dosage5ml Pharmacological propertiesPharmacodynamicsDiavitol is an ultrafiltrate of the blood of dairy calves. The drug improves the transport of oxygen and glucose to cells, which leads to antihypoxic effects, activates reparative and regenerative processes in tissues. Pharmacokinetics The study of the pharmacokinetic parameters of the drug is not possible, because it consists of components that are usually present in the body. Indications for use The drug Diavitol is used in complex therapy: Metabolic and vascular disorders of the brain (including dementia). Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers). Diabetic polyneuropathy. Ulcers of various etiologies, burns, trophic disorders (pressure sores), impaired wound healing processes. Dosage and administration The solution for injection has a slightly yellowish color. The color intensity of the drug from different series may vary due to the raw materials used. Color does not affect the efficacy and tolerability of the drug. DIAVITOL solution for injection can be administered intravenously (in / in), intramuscularly (in / m), it can also be added to solutions for infusion. When administered as an infusion, 20-50 ml of the drug is added to 200-300 ml of the stock solution (isotonic sodium chloride solution or 5% glucose solution). Rate of infusion: approximately 2 ml/min. When administered as an infusion, general contraindications to infusion therapy should be taken into account, such as decompensated heart failure, pulmonary edema, oliguria, anuria, and hyperhydration. Dosage The usual recommended regimen: considering the clinical symptoms, initially 5-10 ml intravenously or intramuscularly, then 5 ml intravenously or slowly intramuscularly daily or several times a week. Doses depending on the indications for use. In severe conditions, 20-50 ml / day of Diavitol is intravenously dripped for several days until a pronounced clinical effect is achieved. In conditions of moderate severity or exacerbation of chronic diseases, it is administered intravenously or intramuscularly for 14-17 days. When conducting a planned course of treatment, 2-5 ml / day is prescribed intravenously or intramuscularly for 4-6 weeks. The frequency of administration is 1-3 times, depending on the severity of the disease. In diabetic polyneuropathy, treatment begins with intravenous administration of the drug at a dose of 2 ml / day for 3 weeks. Use during pregnancy and lactation Use during pregnancy. During pregnancy, DIAVITOL should be used only if the therapeutic benefit outweighs the potential risk to the fetus. Use during breastfeeding. During breastfeeding, DIAVITOL should be used only if the therapeutic benefit outweighs the potential risk to the child. Precautions For parenteral administration of DIAVITOL, sterility must be observed during manipulations. DIAVITOL is intended for single use as it does not contain preservative additives. Opened ampoules and the prepared solution should be used immediately. Unused drug and used consumable must be disposed of in accordance with local regulations. When mixing the contents of DIAVITOL ampoules with other solutions for injection or infusion, physical and chemical incompatibility, as well as interaction between active substances, cannot be ruled out even if the solution remains clear. As a result, it is unacceptable to mix DIAVITOL with other drugs, with the exception of those mentioned in the section “Method of application and dosage”. When administered intramuscularly, DIAVITOL should be administered slowly, no more than 5 ml, since the solution is hypertonic. Parenteral administration of DIAVITOL should be carried out under medical supervision in the presence of appropriate means for the treatment of allergic reactions. Due to the possibility of anaphylactic reactions, a test infusion/injection (hypersensitivity test) is recommended before starting therapy. Do not use a solution that is cloudy or with visible solids. It is a source of sodium, which should be considered when prescribing to patients on a controlled sodium diet. In the presence of electrolyte disturbances (such as hyperchloremia and hypernatremia), adequate correction should be carried out. The drug DIAVITOL is made from the blood of dairy calves. Therefore, it contains potassium, and the same precautions apply to other potassium-containing drugs. Particular caution should be exercised in patients with conditions for which elevated serum potassium poses a particular risk (eg, hyperkalemia, renal insufficiency, cardiac arrhythmias, acute myocardial infarction), and in all conditions for which drugs are prescribed that increase the level serum potassium content. Interaction with other drugs The solution for injection is compatible with isotonic sodium chloride solution and isotonic glucose solution. Diavitol is not recommended to be mixed with other solutions, except for the above. There are no data on the interaction of Diavitol with other drugs. It is necessary to be especially careful when using Diavitol together with drugs that increase the level of potassium in the serum, such as potassium preparations, ACE inhibitors, potassium-sparing diuretics. ContraindicationsIndividual intolerance to the components of the drug. Due to possible allergic reactions, treatment with the drug should not be administered to patients with a known allergy (patients with atopy or milk allergy). Composition Composition per ampoule – 2 ml – 5 ml – 10 ml Diavitol-Ferein – 2 ml – 5 ml – 10 ml Sodium chloride – 20 mg – 50 mg – 100 mg 140 g / l solution of hydrochloric acid or 1 M sodium hydroxide solution pH 6, 2-6,6 Overdose There are currently no reports of drug overdose. Side effect Diavitol is usually well tolerated. Rarely, anaphylakoid (allergic) reactions, anaphylactic shock can occur, which can manifest themselves: from the immune system: skin flushing, rash, itching, urticaria, increased sweating, chills, swelling of the skin and / or mucous membranes, antioneurotic edema, hot flashes, fever body; from the digestive tract: dyspeptic phenomena, including pain in the epigastric region, nausea, vomiting, diarrhea; from the side of the cardiovascular system: pain in the heart area, increased heart rate (tachycardia), shortness of breath, acrocyanosis, pallor of the skin, arterial hypotension or hypertension; from the respiratory system: increased breathing, a feeling of constriction in the chest, difficulty swallowing and / or breathing, sore throat, choking attack; from the nervous system: headache, general weakness, dizziness, loss of consciousness, agitation, tremor (tremor), parasthesia; from the musculoskeletal system: muscle and / or joint pain, back pain; general disorders: reactions at the injection site. If adverse reactions occur, treatment with Diavitol should be discontinued and symptomatic therapy applied. Storage conditions In a place protected from light at a temperature of 2 ° C to 8 ° C. Keep out of the reach of children. Buy Diavitol solution for injection in ampoules 5ml №5×2